Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABCELLERA BIOLOGICS INC.

(ABCL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
19.8(c) 20.36(c) 20.65(c) 21.08(c) 21.035 Last
6 508 789 14 636 227 4 906 015 3 426 074 798 906 Volume
+5.26% +2.83% +1.42% +2.08% -0.21% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 264 M - -
Net income 2021 96,3 M - -
Net cash position 2021 680 M - -
P/E ratio 2021 63,9x
Yield 2021 -
Sales 2022 107 M - -
Net income 2022 -72,6 M - -
Net cash position 2022 482 M - -
P/E ratio 2022 -81,9x
Yield 2022 -
Capitalization 5 875 M 5 875 M -
EV / Sales 2021 19,6x
EV / Sales 2022 50,5x
Nbr of Employees 302
Free-Float 68,5%
More Financials
Company
AbCellera Biologics Inc. (AbCellera) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning,... 
More about the company
Ratings of AbCellera Biologics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ABCELLERA BIOLOGICS INC.
09/21ABCELLERA BIOLOGICS : Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivi..
PU
09/21ABCELLERA BIOLOGICS : Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera..
BU
09/17AFTER HOURS WATCH LIST SCORECARD : Abcl, fang, grts
MT
09/17ABCELLERA BIOLOGICS : Health Care Stocks Down to End Week
MT
09/17Health Care Stocks Mixed Premarket Friday
MT
09/17ABCELLERA BIOLOGICS : Lilly Announce Expanded FDA Emergency Use Authorization for COVID-19..
MT
09/16MT NEWSWIRES AFTER HOURS WATCH LIST : Abcl, fang, grts
MT
09/16ABCELLERA BIOLOGICS : Jumps 20% After Hours as FDA Expands Emergency Use Authorization for..
MT
09/16ABCELLERA BIOLOGICS : Lilly Announce Expanded FDA Emergency Use Authorization for COVID-19..
MT
09/16ABCELLERA BIOLOGICS : Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Adm..
BU
09/16Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etes..
CI
09/15ABCELLERA BIOLOGICS : Acquisition expands AbCellera's existing capabilities to unlock diff..
PU
09/15ABCELLERA BIOLOGICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/15ABCELLERA BIOLOGICS : Moderna Enter mRNA-Encoded Antibody Therapeutic Collaboration
MT
09/15ABCELLERA BIOLOGICS : Announces Collaboration with Moderna to Discover Therapeutic Antibod..
BU
More news
News in other languages on ABCELLERA BIOLOGICS INC.
09/17Les actions du secteur de la santé en baisse à la fin de la semaine
09/17AbCellera et Lilly annoncent l'extension de l'autorisation d'utilisation d'urgence de l..
09/16AbCellera fait un bond de 20 % après les heures d'ouverture, la FDA ayant étendu l'auto..
09/16AbCellera et Lilly annoncent une autorisation d'utilisation d'urgence élargie de la FDA..
09/13AbCellera Biologics rachète TetraGenetics
More news
Analyst Recommendations on ABCELLERA BIOLOGICS INC.
More recommendations
Chart ABCELLERA BIOLOGICS INC.
Duration : Period :
AbCellera Biologics Inc. Technical Analysis Chart | ABCL | CA00288U1066 | MarketScreener
Technical analysis trends ABCELLERA BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 21,08 $
Average target price 45,40 $
Spread / Average Target 115%
EPS Revisions
Managers and Directors
Carl Lars G. Hansen President, Chief Executive Officer & Director
Andrew Booth Chief Financial Officer
Marcie Thiessen Finance Director
Ester Falconer Chief Technology Officer
Véronique Lecault Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
ABCELLERA BIOLOGICS INC.-47.61%5 875
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021